This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olive, K. P. Articles by Tuveson, D. A. Search for Related Content PubMed PubMed Citation Articles by Olive, K. P. Articles by Tuveson, D. A.

The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics

Authors' Affiliations: Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania and Cambridge Research Institute/Cancer Research UK, University of Cambridge, Cambridge, United Kingdom

Requests for reprints: Kenneth P. Olive, Cambridge Research Institute/Cancer Research UK, University of Cambridge, Robinson Way, Cambridge, CB2 2RE, United Kingdom. Phone: 44-1223-404301; E-mail: ken.olive{at}cancer.org.uk or David A. Tuveson, Cambridge Research Institute/Cancer Research UK, University of Cambridge, Robinson Way, Cambridge, CB2 2RE, United Kingdom. Phone: 44-1223-404300; E-mail: david.tuveson{at}cancer.org.uk.

The use of genetically engineered cancer-prone mice as relevant surrogates for patients during the development of pertinent clinical applications is an unproven expectation that awaits direct demonstration. Despite the generally disappointing findings using tumor xenografts and certain early transgenic cancer models to predict therapeutic efficacy in patients, the dramatic progress of mouse models in recent years engenders optimism that the newest generation of mouse models will provide a higher standard of predictive utility in the process of drug development.

This article has been cited by other articles:

				S. Kikuchi, K. Honda, H. Tsuda, N. Hiraoka, I. Imoto, T. Kosuge, T. Umaki, K. Onozato, M. Shitashige, U. Yamaguchi, et al. Expression and Gene Amplification of Actinin-4 in Invasive Ductal Carcinoma of the Pancreas Clin. Cancer Res., September 1, 2008; 14(17): 5348 - 5356. [Abstract] [Full Text] [PDF]

				C. Abate-Shen, P. H. Brown, N. H. Colburn, E. W. Gerner, J. E. Green, M. Lipkin, W. G. Nelson, and D. Threadgill The Untapped Potential of Genetically Engineered Mouse Models in Chemoprevention Research: Opportunities and Challenges Cancer Prevention Research, August 1, 2008; 1(3): 161 - 166. [Abstract] [Full Text] [PDF]

				B. Hegedus, D. Banerjee, T.-H. Yeh, S. Rothermich, A. Perry, J. B. Rubin, J. R. Garbow, and D. H. Gutmann Preclinical Cancer Therapy in a Mouse Model of Neurofibromatosis-1 Optic Glioma Cancer Res., March 1, 2008; 68(5): 1520 - 1528. [Abstract] [Full Text] [PDF]